|1.||Min, Do Sik: 28 articles (01/2015 - 04/2002)|
|2.||Foster, David A: 17 articles (03/2015 - 03/2003)|
|3.||Gomez-Cambronero, Julian: 12 articles (09/2015 - 06/2005)|
|4.||Frohman, Michael A: 10 articles (12/2015 - 05/2005)|
|5.||Gabizon, Alberto: 10 articles (06/2015 - 04/2006)|
|6.||Drenth, Joost P H: 9 articles (10/2015 - 12/2005)|
|7.||Kang, Dong Woo: 9 articles (08/2014 - 02/2008)|
|8.||Torres, Vicente E: 8 articles (08/2015 - 07/2009)|
|9.||Park, Mi Hee: 8 articles (01/2015 - 12/2007)|
|10.||Ahn, Bong-Hyun: 8 articles (02/2009 - 04/2002)|
05/15/2010 - "The three-dose regimen was used in confirmatory studies, which showed that IL-PLD produced significantly greater tumor volume reduction and enhanced survival versus PLD. "
01/01/2014 - "In summary, these data define a PKC-driven oncogenic signaling pathway that requires both PLD and mTOR, and suggest that inhibitors of PLD or mTOR would be beneficial in cancers where PKC overexpression is a contributing or driving factor."
10/01/2010 - "Seven of the 12 patients underwent further assessment of LVEF by echocardiography or multiple gated acquisition scan, which revealed a stable or improved ejection fraction.PLD is cardiac safe for long-term treatment of metastatic solid tumors. "
08/01/2008 - "PLD has also been shown to improve time to tumor progression when used as maintenance therapy. "
08/01/2007 - "We sought to investigate the toxicity and efficacy of PLD in gynecologic cancer patients with CKD. "
|2.||Ovarian Neoplasms (Ovarian Cancer)
08/01/2009 - "PLD is safe and effective in patients with relapsed ovarian cancer, even after numerous previous treatment regimens. "
09/01/2013 - "This phase I study evaluated the safety, tolerability, and biologic activity of SB-485232 administered in combination with PLD in subjects with recurrent ovarian cancer. "
01/01/2013 - "We performed a meta-analysis of randomized trials in order to elucidate the role of PLD in ovarian cancer. "
12/01/2006 - "The encouraging results prompted us to plan a subsequent clinical study of PLD against ovarian cancer."
11/01/2004 - "Several phase II studies showed promising activity of PLD in recurrent ovarian cancer patients with response rate ranging from 16 to 25%. "
|3.||Breast Neoplasms (Breast Cancer)
12/27/2011 - "PLD is a safe and effective treatment for elderly breast cancer patients. "
04/01/2013 - "Based on our limited experience, PLD and CM may be reasonable options for further study for elderly vulnerable patients with endocrine nonresponsive breast cancer."
01/01/2010 - "This observational study supports the activity and tolerability of PLD in metastatic breast cancer as demonstrated in PLD clinical trials."
01/01/2007 - "This community-based observational study supports previous reports indicating that PLD at a median dose of < or =40 mg/m(2) every 4 weeks is an active, well-tolerated agent in non-selected, pretreated patients with metastatic breast cancer."
01/01/2006 - "The favorable safety profile observed in this study leads us to recommend the use of PLD 40 mg/m(2) every 4 weeks for patients with advanced breast cancer."
|4.||Neoplasm Metastasis (Metastasis)
01/01/2014 - "Eventhough the end results of PLD action as relates to downstream signaling mechanisms are still currently being elucidated, invasion, a pre-requisite for metastasis, is directly affected by PLD. "
06/01/2012 - "PLD may be of potential benefit in the prediction of neck metastasis in PTMC."
06/01/2012 - "Univariate and multivariate analyses revealed high PLD as the only independent variable predictive of neck metastasis. "
06/01/2012 - "Patients with high PLD (>8.0) showed higher rates of neck metastases than low PLD (≤ 8.0) (74.0% vs 46.8%, p = .03). "
04/01/2010 - "On the other hand, PLD showed no correlation with regional metastasis. "
02/01/2013 - "Patient demographics, PLD dose, ADEs, use of supportive care interventions, disease progression, and survival were extracted. "
03/01/2008 - "Patients were treated with PLD at a dose of 20 mg/m(2) intravenously every 3 weeks until disease progression or the occurrence of intolerable side effects. "
01/01/2004 - "PLD was administered at the dose of 35 mg/m2 q21 until disease progression or unacceptable toxicity. "
04/01/2013 - "The retrospective analysis included medical records of ovarian cancer patients who were treated with PLD due to disease progression after prior therapy. "
09/20/2009 - "This international, phase III study randomly assigned 751 patients to receive either docetaxel 75 mg/m(2) (n = 373) or PLD 30 mg/m(2) followed by docetaxel 60 mg/m(2) every 21 days (n = 378) and continued until disease progression or prohibitive toxicity. "
|1.||pegylated liposomal doxorubicin
|5.||trabectedin (ecteinascidin 743)
|6.||Polycystic liver disease
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|5.||Renal Replacement Therapy (Therapies, Renal Replacement)